BIO-TECHNE Corp Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $45.82 per share for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-24
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2012-09-30 was $55.11.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2026 was $45.82, a 9.33% increase from fiscal 2025.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $41.91, a 25.70% increase from fiscal 2024.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $33.34, a 13.09% increase from fiscal 2023.
- BIO-TECHNE Corp share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $29.48, a 12.29% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|
| 2026-06-30 | $45.82 10-K · filed 2026-08-24 | ||
| 2025-06-30 | $41.91 10-K · filed 2026-08-24 | ||
| 2024-06-30 | $33.34 10-K · filed 2026-08-24 | ||
| 2023-06-30 | $29.48 10-K · filed 2025-08-22 | ||
| 2022-06-30 | $33.61 10-K · filed 2024-08-22 | $134.45 10-K · filed 2022-08-24 | |
| 2021-06-30 | $28.13 10-K · filed 2023-08-23 | $112.53 10-K · filed 2021-08-25 | |
| 2020-06-30 | $157.45 10-K · filed 2022-08-24 | ||
| 2019-06-30 | $95.29 10-K · filed 2021-08-25 | ||
| 2018-06-30 | $111.51 10-K · filed 2020-08-26 | ||
| 2017-06-30 | $71.81 10-K/A · filed 2019-11-06 | ||
| 2016-06-30 | $69.82 10-K · filed 2018-08-27 | ||
| 2015-06-30 | $69.31 10-K · filed 2017-09-07 | ||
| 2014-06-30 | $59.07 10-K · filed 2016-08-29 | ||
| 2013-06-30 | $51.17 10-K · filed 2015-08-31 | ||
| 2012-09-30 | $55.11 10-Q · filed 2012-11-09 | ||
| 2012-06-30 | $50.98 10-K · filed 2014-08-29 | ||
| 2011-06-30 | $41.48 10-K · filed 2013-08-29 | ||
| 2010-06-30 | $44.67 10-K · filed 2012-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |